How SNAC Technology Makes Oral Semaglutide Possible
SNAC is the absorption-enhancing technology that allows semaglutide to survive the harsh stomach environment and be absorbed orally, enabling the first FDA-approved oral GLP-1 receptor agonist.
Quick Facts
What This Study Found
SNAC technology works by three mechanisms: raising local gastric pH to protect semaglutide from acid degradation, shielding the peptide from enzymatic breakdown, and enhancing transcellular absorption across the stomach epithelium — together enabling clinically effective oral delivery of a GLP-1 receptor agonist.
Key Numbers
Oral semaglutide was FDA-approved in 2019. SNAC stands for sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate.
How They Did This
Narrative review summarizing published studies on SNAC technology as an absorption enhancer, focusing on its application in the oral semaglutide formulation (Rybelsus). Covers preclinical absorption studies and clinical pharmacokinetic data.
Why This Research Matters
The ability to take a GLP-1 receptor agonist as a daily pill instead of a weekly injection removes a major barrier to treatment. Many patients with type 2 diabetes are reluctant to start injectable therapies. SNAC technology represents a breakthrough in oral peptide delivery that could be applied to other peptide drugs beyond semaglutide.
The Bigger Picture
Oral delivery of peptide therapeutics has been a major pharmaceutical challenge for decades. The success of SNAC with semaglutide proves that oral peptide delivery is achievable at therapeutic levels, potentially paving the way for oral formulations of other injectable peptide drugs — from insulin to growth hormone analogs.
What This Study Doesn't Tell Us
SNAC-based oral semaglutide has lower bioavailability compared to injectable semaglutide, requiring higher doses. The strict dosing requirements (empty stomach, minimal water, 30-minute fast) may reduce real-world adherence. This is a narrative review, not a systematic review with formal quality assessment of included studies.
Questions This Raises
- ?Can SNAC technology be successfully applied to other therapeutic peptides beyond semaglutide?
- ?Will next-generation absorption enhancers improve oral peptide bioavailability enough to match injectable formulations?
Trust & Context
- Key Stat:
- First oral GLP-1 agonist SNAC-enabled oral semaglutide (Rybelsus) became the first FDA-approved oral GLP-1 receptor agonist in 2019, overcoming decades of challenges in oral peptide delivery
- Evidence Grade:
- Strong evidence base — this review summarizes well-established pharmacokinetic and clinical data supporting an already FDA-approved product with extensive Phase 3 trial data (PIONEER program).
- Study Age:
- Published in 2024, providing an up-to-date summary of SNAC technology after several years of real-world clinical use of oral semaglutide.
- Original Title:
- Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
- Published In:
- Clinical diabetes : a publication of the American Diabetes Association, 42(1), 74-86 (2024)
- Authors:
- Solis-Herrera, Carolina(2), Kane, Michael P, Triplitt, Curtis(3)
- Database ID:
- RPEP-09294
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why can't you just swallow a regular semaglutide pill without SNAC?
Semaglutide is a peptide — essentially a small protein — and your stomach is designed to break down proteins. Without SNAC's protective and absorption-enhancing effects, stomach acid and digestive enzymes would destroy the semaglutide before it could be absorbed into your bloodstream.
Why do you have to take oral semaglutide on an empty stomach?
Food in the stomach interferes with SNAC's ability to create a protective environment around the semaglutide tablet. The tablet needs direct contact with the stomach lining for SNAC to enhance absorption. Food and excess liquid dilute SNAC's local effects and reduce how much semaglutide gets absorbed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09294APA
Solis-Herrera, Carolina; Kane, Michael P; Triplitt, Curtis. (2024). Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.. Clinical diabetes : a publication of the American Diabetes Association, 42(1), 74-86. https://doi.org/10.2337/cd22-0118
MLA
Solis-Herrera, Carolina, et al. "Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.." Clinical diabetes : a publication of the American Diabetes Association, 2024. https://doi.org/10.2337/cd22-0118
RethinkPeptides
RethinkPeptides Research Database. "Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Ami..." RPEP-09294. Retrieved from https://rethinkpeptides.com/research/solis-herrera-2024-current-understanding-of-sodium
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.